Repros Therapeutics and Adventrx Pharmaceuticals Presenting at the 2010 Sunshine on Wall Street Healthcare Dinner Conference
October 13 2010 - 12:47PM
Repros Therapeutics, Inc. (Nasdaq:RPRX) and Adventrx
Pharmaceuticals, Inc. (AMEX:ANX) will be in Fort Lauderdale,
Florida on October 13th, 2010 for Sunshine on Wall Street, hosted
by LDV Capital Management, in conjunction with the Stock and Bond
Club of South Florida.
Founded in 1965, the Stock and Bond Club of South Florida is the
largest association of investment advisors in South Florida. The
dinner affair will be from 5:30 p.m. to 8:05 p.m. at DeerCreek
Country Club at 2801 Country Club Boulevard, Deerfield Beach,
Florida 33442.
DINNER FORMAT: |
Cocktail hour: 5:30
p.m. to 6:20 p.m. |
Dinner Begins: 6:30
p.m. to 7:15 p.m. |
Presentation 1: 6:45
p.m. to 7:15 p.m. |
Presentation 2: 7:20
p.m. to 7:50 p.m. |
Lightning Round Closing Summary:
7:50 p.m. to 8:00 p.m. |
PRESENTING COMPANIES:
REPROS THERAPEUTICS,
INC., (Nasdaq:RPRX), focuses on the development
of oral small molecule drugs for the treatment of male and female
reproductive disorders. The company's primary product candidate
includes Androxal that completed Phase IIb proof-of-concept trial
in men being treated for low testosterone levels who want to
improve or maintain their fertility and/or sperm number and
function; and is in the Phase IIa clinical trial for the treatment
of hypogonadal men with type 2 diabetes. It also offers
phentolamine-based product candidates, including VASOMAX for the
treatment of male erectile dysfunction. Repros Therapeutics, Inc.
was founded in 1987 and is based in The Woodlands, Texas.
http://www.reprosrx.com.
ADVENTRX PHARMACEUTICALS, INC., (AMEX:ANX),
focuses on in-licensing, developing, and commercializing
proprietary product candidates for the treatment of cancer. Its
lead product candidates include ANX-530, (aka
Exelbine™), an emulsion formulation of chemotherapy drug
vinorelbine to treat advanced non-small cell lung cancer as a
single agent or in combination with cisplatin, as well as to treat
advanced or metastatic breast cancer; and ANX-514, an emulsion
formulation of the chemotherapy drug docetaxel for the treatment of
breast, non-small cell lung, prostate, gastric, and head and neck
cancers. The company was founded in 1995 is headquartered in San
Diego, California. http://www.adventrx.com
To expedite registration, call LDV Capital Management at:
954-746-3117, www.LdvCapitalManagement.com, or email
Jim@LdvCapitalManagement.com.
DISCLAIMER: LDV Capital Management is a Registered Investment
Advisory firm licensed with the State of Florida. The information
herein is not a solicitation to invest, but simply information
compiled from company press releases and company public
information. Information is believed to be reliable, but makes no
representation to its accuracy or completeness. LDV does not
recommend, warrant, or guarantee the success of any action taken in
reliance on statements made in this news release or by any company
presentations at the Conference. Due-diligence and professional
advice should be sought before making any investment decisions. As
in any investment, risks apply, where part of or all investment
capital can be lost. Presenting Companies paid a sponsorship fee to
present at the Conference. Scheduled times, agendas, and presenters
are subject to change. LDV, nor any of its principles or employees
do not hold any stock positions in any of the companies mentioned
above.
CONTACT: LDV Capital Management
954-746-3117
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024